Global HERG Screening Market By Product Type: (Gene KCNH2, Mutant KCNH2) By Ion-Channel: (Voltage-Gated, Ligand Gated) By Drug Type: (Antiarrhythmic, Antipsychotic, Antibiotic) by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast to 2032.

HERG Screening Market Overview:

The global HERG Screening Market market is projected to reach a valuation of USD 6,320.94 Mn by 2032 at a CAGR of 13.85%, from USD 1,517.46 Mn in 2021.

hERG or the human Ether-a-go-go-Related Gene has used the contribution to the activity of the heart. Its channels moderate repolarizing current in the cardiac action potential, which helps in a heart’s beating. It codes the protein known as Kv11.1, the alpha subunit of a potassium ion channel. hERG assessments have become a priority requirement from regulatory agencies before the submission of an investigational new drug. Some of the hERG screening assays are manual/automatic patch-clamp assay, hERG radioligand binding assay, fluorescence polarization assay, and microelectrode array.

In the automatic patch-clamp assay, hERG current is recorded in different concentrations. It is done before and after exposure to test compounds. Then the IC50 values are determined by a technique called dose formulation analysis. Likewise, the other assays are also performed as per their respective norms. hERG screening poses various advantages – it has the presence of a channel that acts as the target for class III antiarrhythmic drugs like amiodarone. It prolongs the action potential and reduces the risk of re-entrant arrhythmias. It can be used in the treatment of diseases like cancer, recurrent epileptic seizures, and schizophrenia by playing the role of a diagnostic marker.

Detailed Segmentation:

The global hERG Screening market is segmented on the basis of – product type, ion-channel type, drug type, and region.

By Product Type:

• Gene KCNH2
• Mutant KCNH2

By Ion-Channel:

• Voltage-Gated
• Ligand Gated

By Drug Type:

• Antiarrhythmic
• Antipsychotic
• Antibiotic

By Region:

• North America
• Europe
• APAC
• South America
• MEA

Market Dynamics:

hERG screening poses various advantages – it has the presence of a channel that acts as the target for class III antiarrhythmic drugs like amiodarone. It prolongs the action potential and reduces the risk of re-entrant arrhythmias. It can be used in the treatment of the diseases such as cancer, recurrent epileptic seizures, schizophrenia by playing the role of a diagnostic marker. hERG channels are involved in cardiac action potential repolarization, and reduced function of hERG lengthens ventricular action potentials, prolongs the QT interval in an electrocardiogram, and increases the risk for potentially fatal ventricular arrhythmias. An increase in the number of R&D activities in this field for new product launches, along with an increase in the approvals for new drug entities are also expected to aid in the economic growth of this market. Furthermore, increasing challenges in developing a biotechnological or pharmaceutical product based on the application is helping to build opportunities for the revenue growth of the hERG screening market. However, the high costs of hERG screening products are expected to potentially hamper the revenue trajectory of the global hERG screening market.

Key Players:

• Abcam PLC
• ABR-Affinity BioReagents Inc.
• AstraZeneca Plc
• Aureus Sciences
• Aurora Biomed Inc.
• AVIVA Biosciences
• B’SYS GmbH
• A PerkinElmer Company
• Cambridge Bioscience Ltd.
• Cellular Dynamics International
• Eurofins-Cerep SA
• ChanTest Corporation
• Charles River Laboratories Inc.
• ChemAxon, Molecular Devices LLC
• Other Key Players

Key Developments:

In July 2017, the acquisition of Discover X was announced by Eurofins Scientific. This is a main agent in the drug discovery products and services from target identification and lead discovery to the preclinical stage and beyond.

In March 2020, Charles River Laboratories partnered with Deciphex. They now work together to develop deep learning-enabled tools to support accelerated pathology analytics.

For the HERG Screening Market research study, the following years have been considered to estimate the market size: